Neurocrine Biosciences reported $3.29 in EPS Earnings Per Share for its fiscal quarter ending in September of 2026.


Fiscal Calendar Actual Consensus Previous Date
FY2026Q3 Sep/2026 3.29 2.05 2.17 Nov/02
FY2026Q2 Jun/2026 2.85 1.58 1.65 Jul/30
FY2026Q1 Mar/2026 1.94 1.15 0.70 May/05
FY2025Q4 Dec/2025 1.88 1.86 1.69 Feb/11
FY2025Q3 Sep/2025 2.17 1.56 1.81 Oct/28




Eps Change Date
AbbVie USD 3.82 0.17 Sep/2026
Acadia Pharmaceuticals USD 0.31 0.13 Sep/2026
Agios Pharmaceuticals USD -1.09 0.6 Sep/2026
ALKERMES USD 0.09 0.09 Sep/2026
Alnylam Pharmaceuticals USD 16.26 14.42 Sep/2026
Amgen USD 6.45 0.16 Sep/2026
Biogen USD 2.62 0.98 Sep/2026
BioMarin Pharmaceutical USD 0.23 0.97 Sep/2026
Cytokinetics USD -1.37 0.13 Sep/2026
Enanta Pharmaceuticals USD -1.05 0.31 Dec/2024
Exelixis USD 0.94 0.03 Sep/2026
Gilead Sciences USD 2.55 9.3 Sep/2026
Halozyme Therapeutics USD 2.39 0.11 Sep/2026
Incyte USD -3.6 6.69 Sep/2026
Ionis Pharmaceuticals USD 0.66 1.35 Sep/2026
Nektar Therapeutics USD -1.78 0.43 Mar/2026
Neurocrine Biosciences USD 3.29 0.44 Sep/2026
Pfizer USD 0.87 0.1 Sep/2026
Prothena USD -0.36 0.96 Jun/2026
Regeneron Pharmaceuticals USD 20.07 5.78 Sep/2026
Repligen USD 0.53 0.01 Sep/2026
Rigel Pharmaceuticals USD 0.7 0.76 Sep/2024
Sarepta Therapeutics USD 0.13 0.51 Sep/2026
Teva Pharmaceutical Industries USD 0.79 0.73 Sep/2026
Ultragenyx Pharmaceutical USD -1.16 0.26 Sep/2026
Vertex Pharmaceuticals USD 4.76 0.03 Sep/2026